The Reaction To Valsartan Impurities: More Scrutiny, More Testing And Tighter Limits
Potent Carcinogens Stir Up Anxieties Over Unknown Unknowns In Pharmaceutical Process Chemistry
Executive Summary
In the months since US and EU authorities restricted Zhejiang Huahai’s market access over the discovery of nitrosamine impurities in its valsartan API, the broader regulatory consequences for drug manufacturers are coming into focus.
You may also be interested in...
Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow
FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.